Worried about Your Memory?
HOPE4MCI is a research study for patients diagnosed with mild cognitive impairment due to Alzheimer’s disease (MCI due to AD). Hope4MCI (Phase 2b trial) data acquisition was completed November 2, 2022 (last patient visit). The database lock and unblinding will now occur Q4 2022, with data analysis forthcoming in Q1 2023.
The HOPE4MCI Research Trial
The HOPE4MCI Alzheimer’s Trial is assessing the efficacy and safety of an investigational medication to determine if it can treat the symptoms associated with Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD) and control further progression leading to the onset of Alzheimer’s dementia.
What is MCI due to AD?
MCI due to AD is a medical condition between normal aging and early Alzheimer’s dementia during which patients experience memory problems.
Clinical Trials
Clinical trials are required to test all medications before they are approved and available for doctors to prescribe. Volunteers for medical research are essential to evaluate treatments.
Keep Me Posted
We will update you when new information is available on HOPE4MCI.org.